IMPORTANCE Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in this disease.
1
World Health Organization classification distinguishes 2 morphological variants of ES: the classic type and the proximal type, both predominantly integrase interactor 1 (INI1) deficient. [2] [3] [4] The prognosis in ES is serious, especially for proximal type, with a 5-year overall survival (OS) rate of 50%. 1 In metastatic patients, the reported median survival is approximately 12 months.
5-9
The current knowledge on the activity of commonly used drugs for sarcoma in ES is based on limited retrospective studies. 8, [10] [11] [12] [13] This is particularly relevant today, when new target agents potentially active in this disease are under evaluation.
14 The aim of this international, collaborative study, including 17 referral sarcoma centers in Europe, the United States, and Japan participating in the World Sarcoma Network effort, was to report on the activity of anthracycline-based regimens, gemcitabine-based regimens, and pazopanib in adult patients with advanced ES.
Methods

Population
We considered all patients with locally advanced/metastatic ES, diagnosed between January 1990 and June 2016, treated with anthracycline-based, gemcitabine-based regimens, or pazopanib. Patients treated with adjuvant/neoadjuvant intent were excluded. Approval by the institutional review board of each institution was obtained, and written informed consent was obtained as required by local regulation.
Study Design
Data were extracted from clinical databases. The diagnosis and morphological subtype were reviewed and confirmed by each institutional sarcoma pathologist. Treatment response was assessed according to RECIST 1.1.
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Statistical Analyses
Descriptive statistics were used to summarize population characteristics. Comparisons between response rates were made using Fisher exact tests.
Progression-free survival (PFS) and OS were estimated by using Kaplan-Meier method, distributions by group were compared through log-rank tests. Progression-free survival was calculated from the treatment start to the first documented evidence of progressive disease (PD), death owing to any cause, or last follow-up. Patients undergoing surgery after medical treatments were censored at the time of PD after surgical resection or at the last follow-up. Overall survival was calculated from the treatment start to the time of death from any cause or the last follow-up. A 2-sided P < .05 was considered statistically significant. Statistical analyses were carried out with SAS (version 9.4, SAS Institute Inc) and R statistical software (version 3.4.0, R Foundation).
Results
Population
One-hundred-fifteen patients with locally advanced/metastatic ES treated with an anthracycline-based regimen, gemcitabinebased regimen, or pazopanib were identified. Among them, 80 (70%) were men and 35 (30%) were women. The median age in the population was 32 years (range, 15-77 years 
Treatment Response and Outcome
Eighty-five, 41, and 18 patients were included in the anthracycline group, gemcitabine group, and pazopanib group, respectively. Twenty-four patients received more than 1 of the selected treatments. eTables 1 and 2 in the Supplement report treatment details.
Anthracycline-Based Regimens
Best RECIST response for anthracycline-based regimens was 1 complete response (CR, 1%), 18 (21%) partial response (PR), 45 (53%) stable disease (SD), and 21 (25%) PD. The response rate was 22%.
The median PFS was 6 (IQR, 2.3-10.4) months. The median PFS in responding patients was 9 months (IQR, 4.6-20.6), 7 in proximal type (IQR, (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) , and 9 in classic type ES (IQR, 7-not evaluable [NE] ). The median PFS in nonresponding patients was 5 months (IQR, 2.2-9.2), 4 in proximal type (IQR, 2-9), and 5 in classic type ES (IQR, (3) (4) (5) (6) (7) (8) (9) (10) . The median OS (all lines of therapy considered together) was 16 months (IQR, ).
Gemcitabine-Based Regimens
Best RECIST response for gemcitabine-based regimens was 2 (5%) CR, 9 (22%) PR, 16 (39%) SD, and 14 (34%) PD. The response rate was 27%.
The median PFS was 4 (IQR, 2.0-11.9) months. The median PFS in responding patients was 16 months (IQR, 7.1-NE),
Key Points
Question Are anthracycline-based regimens, gemcitabine-based regimens, and pazopanib active in advanced epithelioid sarcoma (ES)?
Finding This multi-institutional case series included 115 patients with advanced ES treated with anthracycline-based regimens (85), gemcitabine-based regimens (41), or pazopanib (18) between 1990 and 2016 at 17 sarcoma centers in Europe, the United States, and Japan. The response rate and the median progression-free survival (PFS) in the anthracycline-group were 22% and 6 months; 27% and 4 months in the gemcitabine-group; 0 and 3 months with pazopanib.
Meaning Anthracycline-based and gemcitabine-based regimens are moderately active in advanced ES, with similar response rates and PFS, whereas the activity of pazopanib seemed limited. 20 in proximal type (IQR, 13-NE), and 10 in classic type ES (IQR, 7-NE). The median PFS in nonresponding patients was 3 months (IQR, 1.7-6.2), 3 in both proximal type and classic type. The median OS was 19 months (IQR, 8.9-37.3).
Pazopanib
Best RECIST response with pazopanib was 9 (50%) SD and 9 (50%) PD. Two prolonged SD were observed (27 and 21 months). The median PFS and OS were 3 (IQR, 2.1-11.2) and 14 (IQR, 5-33.1) months, respectively. eTable 3 in the Supplement reports response rate, median PFS, and median OS by subtype, primary site, and response to treatment. eTable 4 in the Supplement reports population outcome. The Figure shows Kaplan-Meier curves for PFS.
Discussion
To our knowledge, this international retrospective study collected the largest series currently available of patients with advanced ES treated with systemic therapy. One hundred fifteen patients were included. Anthracycline-based regimens (response rate, 22%) and gemcitabine-based regimens (response rate, 27%) are active in a proportion of patients with ES. A trend toward a higher response rate to anthracyclinebased regimens was noticed in pathologic proximal type compared with classic type ES, and in patients with anatomically proximal tumor sites. However, duration of response was low, particularly in proximal type ES. In the gemcitabinebased treatment group, the response rate was slightly higher in patients with morphological classic type ES and distal primary sites. No responses were seen with pazopanib and PFS was low.
Given the rarity of ES, collaborative retrospective efforts are of major relevance to provide clinical guidance. With all the limitations of a retrospective study, our case series is the largest available on the activity of systemic therapies for patients with ES. Updated follow-up was available for more than 90% of patients, though with some limitations (since the date of last radiological assessment was unknown in some cases, patients were censored at the time of the last follow-up). Pathologic diagnosis was confirmed by a dedicated sarcoma pathologist and INI1 status was known in most cases.
In our series anthracycline-based regimens were associated with an response rate of 22% and a 6-month median PFS. Of 3 published retrospective studies, results are conflicting about tumor response rate to anthracycline (ranging from 0 to 43%) and PFS (3 to 8 months). 8, 10, 13 In our series, we observed responses both in classic type (19%) and in proximal type (26%). However, the median PFS in responding patients was low (9 months), particularly for proximal type ES. Our data might therefore encourage the use of anthracyclines in the proximal type, especially if some integration with surgery is foreseen. With gemcitabine-based regimens, we observed an response rate of 27% and a median PFS of 4 months, confirming what was previously reported by Pink et al 10 (response rate, 58%; PFS, 8 months). The responses observed by Pink and colleagues were similar in both subtypes, whereas in our study gemcitabine-based regimens appeared slightly more active in classic type ES (30% vs 22%) and distal primary site. A favorable PFS was observed in responding patients of both subtypes, especially in the proximal type subgroup. In distal type ES the natural history of disease may be a confounding factor. The activity of pazopanib in our study was limited. Notably, pazopanib was mainly used in further line and in a limited number of patients. A long-lasting PR in a proximal type ES (INI1 undetermined) treated in first-line has been reported.
11
Although we cannot exclude the activity of pazopanib in some cases, it seems inferior to anthracycline-based and gemcitabine-based regimens.
Conclusions
Although the number of patients was low, we observed signs of a differential activity of anthracycline-based and gemcitabine-based regimens between the 2 ES variants. Unfortunately, we were not able to further break down distal ES according to their more or less aggressive morphologic appearance, in a disease regarded today as high-grade by definition. Indeed, a degree of heterogeneity can be observed upfront and across relapses. A further subtype-adapted grading system based on pathologic features and its correlation with treatment response would be interesting to explore. We also hope that this report will provide a benchmark for future trials on medical agents in this disease.
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